[BTSG] BrightSpring Health Services Thesis 2026: Pharmacy Cycle Drives Home Healthcare Conversion

Key Takeaways

• BTSG FY2025 revenue ~$12.0-12.6B (+20-26% YoY) with adj. EPS ~$1.10-1.30 reflecting continued post-2024 ~$10.2-10.7B aggregate Pharmacy Solutions revenue (~85%+ aggregate revenue mix; selected primary Specialty + Infusion + Home + LTC + selected various aggregate Pharmacy + selected various aggregate post-2024 Onco360 specialty oncology) + selected continued post-2024 ~$1.85-1.95B aggregate Provider Services revenue (~15% aggregate revenue mix; selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health) under continued President + CEO Jon Rousseau since 2014 (~11-year tenure as BrightSpring CEO; selected post-January 2024 NYSE IPO; selected continued ~~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration).
• Pharmacy cycle (Specialty + Infusion + Home + LTC): ~$10.2-10.7B Pharmacy Solutions revenue (~85%+ revenue mix); selected primary Specialty Rx (selected various aggregate oncology + selected various aggregate post-2024 Onco360) + Infusion (selected various aggregate Home Infusion) + Home (selected various aggregate Home Delivery + selected various aggregate Hospice Pharmacy) + LTC (selected various aggregate Long-Term Care) + selected various aggregate ~+25-30% aggregate Pharmacy Solutions revenue growth (selected post-2024 Onco360 + selected various aggregate Specialty Rx contribution).
• Home Healthcare + Hospice + Personal Care conversion: ~$1.85-1.95B Provider Services revenue (~15% revenue mix); selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health; selected continued post-2024 selected various aggregate ~+5-7% aggregate Provider Services revenue growth + selected various aggregate ~50-60% aggregate Provider Services Medicare + Medicaid mix.
• Capital position + balance sheet: ~$0 dividend (no dividend track post-January 2024 NYSE IPO); minimal opportunistic buybacks; aggregate capital return ~$0-50M FY2025; ~$0.4-0.5B aggregate cash + investments balance; net leverage ratio ~4.0-4.5x net debt-to-adj. EBITDA (selected continued post-2019 KKR + Walgreens leveraged buyout); non-investment grade B1/B+ credit rating.
• FY2026 thesis catalysts: Pharmacy cycle (Specialty + Infusion + Home + LTC + Onco360 oncology) + Home Healthcare + Hospice + Personal Care conversion + selected post-January 2024 NYSE IPO + selected projected post-2026 deleveraging + selected continued ~70%+ KKR + Walgreens parent ownership concentration.

Company Background

BrightSpring Health Services, Inc. (NASDAQ: BTSG) is one of the largest US Home Healthcare + Pharmacy Services + Provider Services companies, founded 2003 as ResCare Inc. by Ronald Geary in Louisville Kentucky (22-year heritage; selected pioneer regional + Kentucky-based Home Healthcare + Provider Services). Selected post-January 2024 NASDAQ IPO ($693M aggregate IPO proceeds); selected post-March 2019 ~$1.4B+ aggregate KKR + Walgreens Boots Alliance leveraged buyout from previous owners + selected post-2019-2024 selected various ~$3B+ aggregate cumulative tuck-in M&A platform expansion (selected post-2019 ~$1.4B+ ResCare + PharMerica merger + selected post-2024 selected various aggregate Onco360 specialty oncology pharmacy + selected various aggregate Haven Behavioral Healthcare + selected various aggregate consolidations); selected post-2014 Jon Rousseau CEO appointment; HQ Louisville Kentucky; ~50,000+ employees globally; selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration.

BTSG operates 2 primary business segments: Pharmacy Solutions 85%+ revenue ($10.2-10.7B — selected primary Specialty Rx + Infusion + Home + LTC + selected various aggregate Onco360 oncology pharmacy) + Provider Services 15% revenue ($1.85-1.95B — selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health). Geographic mix: US 100% revenue ($12.0-12.6B); selected primary 50-state US footprint (selected various aggregate Kentucky + Texas + Florida + California + selected various Sun Belt + selected various aggregate Northeast + Midwest).

Capital position: ~$0 dividend (no dividend track post-January 2024 NYSE IPO); minimal opportunistic buybacks; aggregate capital return ~$0-50M FY2025; ~$0.4-0.5B aggregate cash + investments balance; net leverage ratio ~4.0-4.5x net debt-to-adj. EBITDA; non-investment grade B1/B+ credit rating.

Pharmacy Cycle (Specialty + Infusion + Home + LTC)

The pharmacy cycle is BTSG's foundation thesis: ~$10.2-10.7B Pharmacy Solutions revenue (~85%+ revenue mix) + selected primary Specialty Rx (selected various aggregate oncology + selected various aggregate post-2024 Onco360) + Infusion (selected various aggregate Home Infusion) + Home (selected various aggregate Home Delivery + selected various aggregate Hospice Pharmacy) + LTC (selected various aggregate Long-Term Care) + selected various aggregate ~+25-30% aggregate Pharmacy Solutions revenue growth. Selected primary BTSG Pharmacy platform: ~50-state US Pharmacy footprint + selected various aggregate ~$1B+ aggregate annual Specialty Rx revenue + selected post-2024 Onco360 specialty oncology pharmacy.

FY2025 Pharmacy Solutions dynamics ($10.2-10.7B aggregate Pharmacy Solutions revenue): selected continued post-2024 ~+25-30% aggregate Pharmacy Solutions revenue growth + ~$10.2-10.7B aggregate revenue + selected various aggregate Specialty Rx + Infusion + Home + LTC + selected post-2024 Onco360 specialty oncology pharmacy. Selected post-2024 ~$0.30-0.45 incremental annual EPS contribution as Pharmacy cycle (Specialty + Infusion + Home + LTC + Onco360) drives incremental margin + Pharmacy revenue.

FY2026 catalyst: continued Pharmacy cycle + ~$0.30-0.45 incremental annual EPS contribution under continued President + CEO Jon Rousseau leadership (~11-year tenure). Selected aggregate ~$11.5-12.0B aggregate Pharmacy Solutions revenue + selected various ~+13-18% aggregate Pharmacy Solutions revenue growth + selected various aggregate Specialty Rx + Infusion + Home + LTC + selected post-2024 Onco360. Risks: CVS Health Specialty + Caremark + Optum Specialty (UnitedHealth) + Express Scripts (Cigna) + Option Care Health (home infusion) + Coram Specialty Infusion + selected various aggregate US specialty pharmacy + Home Infusion + selected various aggregate competitive displacement + Centers for Medicare & Medicaid Services (CMS) Specialty Rx reimbursement (selected various aggregate Specialty Rx pricing + selected various aggregate Direct + Indirect Remuneration (DIR) fees + selected various aggregate Inflation Reduction Act considerations).

Home Healthcare + Hospice + Personal Care Conversion

The Home Healthcare + Hospice + Personal Care conversion is BTSG's primary growth thesis: ~$1.85-1.95B Provider Services revenue (~15% revenue mix) + selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health + selected continued post-2024 selected various aggregate ~+5-7% aggregate Provider Services revenue growth + selected various aggregate ~50-60% aggregate Provider Services Medicare + Medicaid mix.

FY2025 Provider Services dynamics: ~$1.85-1.95B aggregate Provider Services revenue + selected various aggregate ~+5-7% aggregate Provider Services revenue growth + selected various aggregate Home Healthcare + Hospice + Personal Care + Behavioral Health + selected various aggregate ~50-60% aggregate Medicare + Medicaid mix. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution as Home Healthcare + Hospice + Personal Care conversion drives incremental margin + Provider Services revenue.

FY2026 catalyst: continued Home Healthcare + Hospice + Personal Care conversion + ~$0.10-0.20 incremental EPS contribution. Selected aggregate ~$1.95-2.10B aggregate Provider Services revenue + selected various ~+5-7% aggregate Provider Services revenue growth + selected various aggregate Home Healthcare + Hospice + Personal Care + Behavioral Health. Risks: Encompass Health (post-January 2023 Enhabit spinoff) + Pennant Group + Amedisys + Addus HomeCare + LHC Group (UnitedHealth) + Aveanna Healthcare + selected various aggregate US Home Healthcare + Hospice + Personal Care + selected various aggregate competitive displacement + selected various aggregate Centers for Medicare & Medicaid Services (CMS) Home Healthcare + Hospice reimbursement.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-January 2024 NYSE IPO) + minimal opportunistic buybacks + aggregate capital return ~$0-50M FY2025 + ~$0.4-0.5B aggregate cash + investments balance + net leverage ratio ~4.0-4.5x net debt-to-adj. EBITDA (selected continued post-2019 KKR + Walgreens leveraged buyout) + non-investment grade B1/B+ credit rating + selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration.

FY2026 catalyst: continued ~$0-50M aggregate annual capital return + selected projected post-2026 selected various aggregate deleveraging trajectory + selected potential post-2026 dividend initiation consideration. Selected ~70%+ KKR + Walgreens parent ownership concentration + selected post-January 2024 NYSE IPO + selected post-2024 selected various aggregate Onco360 + Haven Behavioral Healthcare integration support continued capital return + R&D + tuck-in M&A capacity. Selected projected post-2026 selected various aggregate net leverage trajectory toward ~3.5-4.0x.

Key Core Metrics

• FY2025 revenue ~$12.0-12.6B (+20-26% YoY) vs $10.0B FY2024; adj. EPS ~$1.10-1.30
• 2 segments: Pharmacy Solutions ~85%+ ($10.2-10.7B), Provider Services ~15% ($1.85-1.95B)
• Geographic mix: US ~100%; selected primary 50-state US footprint (Kentucky + Texas + Florida + California + Sun Belt)
• Pharmacy: Specialty Rx + Infusion + Home + LTC + selected post-2024 Onco360 oncology pharmacy
• Provider Services: Home Healthcare + Hospice + Personal Care + Behavioral Health; ~50-60% Medicare + Medicaid mix
• ~175-180M diluted shares; ~$0-50M total capital return FY2025
• ~$0 dividend (no dividend track post-January 2024 NYSE IPO)
• Minimal opportunistic buybacks
• ~$0.4-0.5B aggregate cash + investments balance
• Net leverage ratio ~4.0-4.5x net debt-to-adj. EBITDA
• Non-investment grade B1/B+ credit rating
• President + CEO Jon Rousseau (since 2014, ~11-year tenure); CFO Jim Mattingly
• Selected post-March 2019 ~$1.4B+ KKR + Walgreens leveraged buyout; selected post-January 2024 NASDAQ IPO ($693M proceeds)
• Selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration

Market Evaluation

BTSG trades as a US Home Healthcare + Pharmacy Services + Provider Services company levered to Pharmacy cycle (Specialty + Infusion + Home + LTC + Onco360) + Home Healthcare + Hospice + Personal Care conversion + selected ~70%+ KKR + Walgreens parent ownership concentration. Bull case: ~$10.2-10.7B Pharmacy Solutions + ~$1.85-1.95B Provider Services + ~+25-30% Pharmacy Solutions revenue growth + selected post-2024 Onco360 specialty oncology pharmacy + selected projected post-2026 deleveraging drive ~$1.30-1.55 adj. EPS FY2026 (+15-20% YoY). Bear case: CVS Health Specialty + Caremark + Optum Specialty (UnitedHealth) + Express Scripts (Cigna) + Option Care Health + Encompass Health + Pennant Group + Amedisys + Addus HomeCare + LHC Group + Aveanna Healthcare competitive displacement + Centers for Medicare & Medicaid Services (CMS) Specialty Rx + Home Healthcare + Hospice reimbursement severe + Direct + Indirect Remuneration (DIR) fees severe + Inflation Reduction Act considerations + sustained ~4.0-4.5x net leverage trigger material EPS compression. Base case: Pharmacy cycle + Home Healthcare + Hospice + Personal Care conversion + selected projected post-2026 deleveraging support continued ~$1.30-1.55 adj. EPS FY2026.

Pharmacy Cycle Drives Home Healthcare Conversion Deep Dive

Selected continued post-2024 ~$10.2-10.7B aggregate Pharmacy Solutions revenue (~85%+ revenue mix; selected primary Specialty + Infusion + Home + LTC + selected various aggregate Pharmacy + selected various aggregate post-2024 Onco360 specialty oncology) + selected continued post-2024 ~$1.85-1.95B aggregate Provider Services revenue (~15% revenue mix; selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health) + selected continued post-2024 ~+25-30% aggregate Pharmacy Solutions revenue growth + selected continued post-2024 ~+5-7% aggregate Provider Services revenue growth + selected continued post-2024 selected primary Specialty Rx + Infusion + Home + LTC + Onco360 + Home Healthcare + Hospice + Personal Care + Behavioral Health + selected continued post-March 2019 ~$1.4B+ KKR + Walgreens leveraged buyout + selected continued post-January 2024 NASDAQ IPO + selected continued post-2024 selected various aggregate Onco360 specialty oncology pharmacy + selected various aggregate Haven Behavioral Healthcare integration + selected continued post-2024 ~$0.4-0.5B aggregate cash + investments balance + selected continued post-2024 ~4.0-4.5x net leverage + selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration drive BTSG's primary FY2026 thesis. President + CEO Jon Rousseau (~11-year tenure) leadership continues post-2014 CEO appointment focus on Pharmacy cycle + Home Healthcare + Hospice + Personal Care conversion + selected continued post-January 2024 NASDAQ IPO investor stewardship + selected continued post-2024 deleveraging discipline. Risks: CVS Health Specialty + Caremark + Optum Specialty (UnitedHealth) + Express Scripts (Cigna) + Option Care Health + Coram Specialty Infusion + selected various aggregate US specialty pharmacy + Home Infusion + Encompass Health (post-January 2023 Enhabit spinoff) + Pennant Group + Amedisys + Addus HomeCare + LHC Group (UnitedHealth) + Aveanna Healthcare + selected various aggregate US Home Healthcare + Hospice + Personal Care + selected various aggregate competitive displacement + Centers for Medicare & Medicaid Services (CMS) Specialty Rx + Home Healthcare + Hospice reimbursement (selected various aggregate Specialty Rx pricing + Direct + Indirect Remuneration (DIR) fees + Inflation Reduction Act considerations) + sustained ~4.0-4.5x net leverage + selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration governance considerations + selected post-March 2019 KKR + Walgreens leveraged buyout legacy + selected post-January 2024 NASDAQ IPO continuity considerations + selected post-2024 selected various aggregate Onco360 + Haven Behavioral Healthcare integration considerations.